Last Reported Results and Surprise History Over the past month, shares of this pharmaceutical company have returned -5.1%, compared to the Zacks S&P 500 composite's +3.1% change. During this period, the Zacks Medical Services industry, which Organon falls in, has gained 0.9%. The key question now is: What could be the stock's future direction? Revisions to Earnings Estimates We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the la ...